HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via Web of Science (2) Citing Articles via Google Scholar Google Scholar Articles by Emmons, G. T. Articles by Jensen, B. K. Search for Related Content PubMed PubMed Citation Articles by Emmons, G. T. Articles by Jensen, B. K. Social Bookmarking                         What's this?

Pharmacokinetics of M100240 and MDL 100,173, a Dual Angiotensin-Converting Enzyme/Neutral Endopeptidase Inhibitor, in Healthy Young and Elderly Volunteers

From the Department of Drug Metabolism and Pharmacokinetics, Aventis Pharmaceuticals, Inc, Bridgewater, New Jersey.

M100240 is an acetate thioester of MDL 100,173—a dual angiotensin-converting enzyme (ACE)/neutral endopeptidase (NEP) inhibitor—in phase II development. The pharmacokinetics of M100240 and MDL 100,173 were compared in young and elderly subjects. Pharmacokinetic data were obtained from 12 young (ages 18-45 years, 10 male, 2 female) and 12 elderly (ages 65-85 years, 7 male, 5 female) healthy subjects in a parallel-group, open-label study. Following an overnight fast, subjects received a single 25-mg oral dose of M100240. Serial plasma concentrations of M100240 and MDL 100,173 were determined using a validated liquid chromatography/tandem mass spectrometry (LC/MS/MS) method, and pharmacokinetic parameters were calculated with noncompartmental methods. Single-dose treatment with M100240 was well tolerated in both groups of subjects, with no clinically significant changes in vital signs, ECG recordings, or laboratory safety parameters. M100240 was rapidly absorbed and converted to MDL 100,173, with M100240 concentrations no longer detectable at 3 to 4 hours postdose in both groups. The pharmacokinetics of the pharmacologically active MDL 100,173 were similar for both groups. Although maximum concentrations of M100240 were generally higher in elderly versus young subjects (C_max 0.48 ng/mL vs. 0.17 ng/mL), systemic availability of M100240 was quite low and variable with plasma, and this apparent difference in parent drug exposure is unlikely to have important clinical implications. No age-related differences in the pharmacokinetic parameters of MDL 100,173 (C_max 8.16 vs. 9.62 ng/mL, t_max 1.25 vs. 1.5 h, AUC_(0-last) 81.6 vs. 72.2 ng•h/mL) were observed between young and elderly subjects, respectively. In conclusion, there are no age-related differences in the pharmacokinetics of MDL 100,173 between young and elderly subjects.

Key Words: Angiotensin-converting enzyme/neutral endopeptidase (ACE/NEP) inhibitor • pharmacokinetics • elderly • M100240 • MDL 100,173 • hypertension

Address for reprints: Gary T. Emmons, PhD, Department of Drug Metabolism and Pharmacokinetics, Aventis Pharmaceuticals, Inc, 1041 Route 202-206, P.O. Box 6800, Bridgewater, NJ 08807-0800.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?